Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum Resistant High Grade Epithelial Ovarian Cancer”

67 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 67 results

Testing effectiveness (Phase 2)Looking for participantsNCT06303505
What this trial is testing

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Who this might be right for
Ovarian CancerNon-small Cell Lung Cancer
Tubulis GmbH 250
Large-scale testing (Phase 3)Study completedNCT04296890
What this trial is testing

Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

Who this might be right for
Epithelial Ovarian CancerPeritoneal CancerFallopian Tube Cancer
ImmunoGen, Inc. 106
Testing effectiveness (Phase 2)Ended earlyNCT05538624
What this trial is testing

Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary

Who this might be right for
Neoplasm, OvarianFallopian Tube CancerPrimary Peritoneal Cavity Cancer+5 more
Avenge Bio, Inc 14
Testing effectiveness (Phase 2)Ended earlyNCT05243524
What this trial is testing

Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

Who this might be right for
Platinum-resistant Epithelial Ovarian Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.) 16
Large-scale testing (Phase 3)Study completedNCT02855944
What this trial is testing

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Who this might be right for
Ovarian CancerEpithelial Ovarian CancerFallopian Tube Cancer+1 more
pharmaand GmbH 349
Early research (Phase 1)Study completedNCT03508570
What this trial is testing

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Who this might be right for
Malignant Peritoneal NeoplasmMalignant Retroperitoneal NeoplasmMetastatic Cervical Carcinoma+31 more
M.D. Anderson Cancer Center 26
Early research (Phase 1)Ended earlyNCT05274451
What this trial is testing

Investigate LYL797 in Adults With Solid Tumors

Who this might be right for
Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerNon-small Cell Lung Cancer+20 more
Lyell Immunopharma, Inc. 57
Large-scale testing (Phase 3)Looking for participantsNCT07218809
What this trial is testing

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Who this might be right for
Epithelial Ovarian Cancer
AstraZeneca 1,100
Testing effectiveness (Phase 2)Looking for participantsNCT04918186
What this trial is testing

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Who this might be right for
Ovarian Cancer
Canadian Cancer Trials Group 60
Large-scale testing (Phase 3)Looking for participantsNCT07546500
What this trial is testing

Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Who this might be right for
Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc 420
Testing effectiveness (Phase 2)Looking for participantsNCT04518501
What this trial is testing

Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer

Who this might be right for
Efficacy and Safety
Xing Xie 50
Large-scale testing (Phase 3)Ended earlyNCT04729608
What this trial is testing

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Ovarian Cancer
Aravive, Inc. 366
Early research (Phase 1)Looking for participantsNCT06799065
What this trial is testing

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

Who this might be right for
Advanced Solid TumorsBreast Cancer RecurrentOvarian Cancer+2 more
Accent Therapeutics 90
Testing effectiveness (Phase 2)Looking for participantsNCT06906341
What this trial is testing

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms+1 more
Corcept Therapeutics 270
Testing effectiveness (Phase 2)UnknownNCT03188159
What this trial is testing

Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube Cancer
National University Hospital, Singapore 36
Early research (Phase 1)Active Not RecruitingNCT04616534
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

Who this might be right for
Advanced Fallopian Tube CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian Carcinoma+19 more
National Cancer Institute (NCI) 14
Testing effectiveness (Phase 2)Ended earlyNCT02012192
What this trial is testing

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Medical University Innsbruck 133
Testing effectiveness (Phase 2)UnknownNCT03509246
What this trial is testing

Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

Who this might be right for
Ovarian Neoplasm EpithelialHigh Grade Serous Carcinoma
Seoul National University Hospital 44
Testing effectiveness (Phase 2)Active Not RecruitingNCT03587311
What this trial is testing

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube Endometrioid AdenocarcinomaFallopian Tube High Grade Serous AdenocarcinomaOvarian Endometrioid Adenocarcinoma+5 more
National Cancer Institute (NCI) 96
Testing effectiveness (Phase 2)Study completedNCT03314740
What this trial is testing

Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib

Who this might be right for
Ovarian Neoplasms
Mario Negri Institute for Pharmacological Research 123
Load More Results